Teva Pharmaceutical Industries PE Ratio 2010-2024 | TEVA
Current and historical p/e ratio for Teva Pharmaceutical Industries (TEVA) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Teva Pharmaceutical Industries PE ratio as of November 20, 2024 is 6.25.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Teva Pharmaceutical Industries PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-11-19 |
16.81 |
|
0.00 |
| 2024-09-30 |
18.02 |
$-0.85 |
0.00 |
| 2024-06-30 |
16.25 |
$-0.39 |
0.00 |
| 2024-03-31 |
14.11 |
$-0.41 |
0.00 |
| 2023-12-31 |
10.44 |
$-0.47 |
0.00 |
| 2023-09-30 |
10.20 |
$-1.98 |
0.00 |
| 2023-06-30 |
7.53 |
$-2.00 |
0.00 |
| 2023-03-31 |
8.85 |
$-1.44 |
0.00 |
| 2022-12-31 |
9.12 |
$-2.12 |
0.00 |
| 2022-09-30 |
8.07 |
$-1.16 |
0.00 |
| 2022-06-30 |
7.52 |
$-0.95 |
0.00 |
| 2022-03-31 |
9.39 |
$-0.55 |
0.00 |
| 2021-12-31 |
8.01 |
$0.38 |
21.08 |
| 2021-09-30 |
9.74 |
$0.66 |
14.76 |
| 2021-06-30 |
9.90 |
$-3.57 |
0.00 |
| 2021-03-31 |
11.54 |
$-3.63 |
0.00 |
| 2020-12-31 |
9.65 |
$-3.64 |
0.00 |
| 2020-09-30 |
9.01 |
$-3.68 |
0.00 |
| 2020-06-30 |
12.33 |
$0.00 |
0.00 |
| 2020-03-31 |
8.98 |
$-0.76 |
0.00 |
| 2019-12-31 |
9.80 |
$-0.92 |
0.00 |
| 2019-09-30 |
6.88 |
$-3.87 |
0.00 |
| 2019-06-30 |
9.23 |
$-3.85 |
0.00 |
| 2019-03-31 |
15.68 |
$-3.46 |
0.00 |
| 2018-12-31 |
15.42 |
$-2.33 |
0.00 |
| 2018-09-30 |
21.54 |
$-10.89 |
0.00 |
| 2018-06-30 |
24.32 |
$-10.10 |
0.00 |
| 2018-03-31 |
17.09 |
$-15.80 |
0.00 |
| 2017-12-31 |
18.95 |
$-16.26 |
0.00 |
| 2017-09-30 |
17.50 |
$-5.95 |
0.00 |
| 2017-06-30 |
32.86 |
$-6.12 |
0.00 |
| 2017-03-31 |
31.37 |
$0.02 |
1568.54 |
| 2016-12-31 |
35.10 |
$0.07 |
501.38 |
| 2016-09-30 |
44.14 |
$1.72 |
25.66 |
| 2016-06-30 |
47.88 |
$1.49 |
32.13 |
| 2016-03-31 |
50.67 |
$1.92 |
26.39 |
| 2015-12-31 |
61.79 |
$1.82 |
33.95 |
| 2015-09-30 |
52.84 |
$2.07 |
25.53 |
| 2015-06-30 |
55.04 |
$2.97 |
18.53 |
| 2015-03-31 |
57.70 |
$3.21 |
17.97 |
| 2014-12-31 |
52.94 |
$3.56 |
14.87 |
| 2014-09-30 |
49.21 |
$3.21 |
15.33 |
| 2014-06-30 |
47.68 |
$3.03 |
15.74 |
| 2014-03-31 |
47.72 |
$1.63 |
29.28 |
| 2013-12-31 |
35.94 |
$1.50 |
23.96 |
| 2013-09-30 |
33.63 |
$1.42 |
23.69 |
| 2013-06-30 |
34.66 |
$0.49 |
70.74 |
| 2013-03-31 |
34.85 |
$2.01 |
17.34 |
| 2012-12-31 |
32.57 |
$2.24 |
14.54 |
| 2012-09-30 |
35.94 |
$2.44 |
14.73 |
| 2012-06-30 |
34.05 |
$3.56 |
9.56 |
| 2012-03-31 |
38.70 |
$3.21 |
12.06 |
| 2011-12-31 |
34.51 |
$3.08 |
11.21 |
| 2011-09-30 |
31.69 |
$3.36 |
9.43 |
| 2011-06-30 |
40.86 |
$3.48 |
11.74 |
| 2011-03-31 |
42.35 |
$3.72 |
11.38 |
| 2010-12-31 |
43.81 |
$3.67 |
11.94 |
| 2010-09-30 |
44.18 |
$3.24 |
13.64 |
| 2010-06-30 |
43.40 |
$2.81 |
15.44 |
| 2010-03-31 |
52.51 |
$2.51 |
20.92 |
| 2009-12-31 |
46.64 |
$2.23 |
20.91 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$19.044B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
